Patient and Physician Perspectives on MSdialog, an Electronic PRO Diary in Multiple Sclerosis [0.03%]
MSdialog电子PRO日记在多发性硬化症患者和医师中的应用观点研究
Peter Greiner,Anna Sawka,Emma Imison
Peter Greiner
Background: MSdialog, a web- and mobile-based software application, captures data on self-administration of subcutaneous interferon β-1a, clinical outcomes, and patient-reported outcomes in patients with multiple scleros...
Content Validity of the Hypogonadism Impact of Symptoms Questionnaire (HIS-Q): A Patient-Reported Outcome Measure to Evaluate Symptoms of Hypogonadism [0.03%]
低睾酮影响症状调查问卷（HIS-Q）的内容效度：评估低睾酮症状的患者报告结果工具
Heather L Gelhorn,Margaret K Vernon,Katie D Stewart et al.
Heather L Gelhorn et al.
Background: Hypogonadism, or low testosterone, is a common disorder. There are currently no patient-reported outcome (PRO) instruments designed to comprehensively evaluate the symptoms of hypogonadism and to detect change...
Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF [0.03%]
一项随机、开放标签、3b期非劣效性研究：HIV成人受试者换用艾维雷韦/考比司他/恩曲他滨/富马酸替诺福韦二吡美.drive片与继续使用蛋白酶抑制剂/恩曲他滨/富马酸替诺福韦二吡美.drive治疗48周的患者报告症状
Joseph Gathe,Jose R Arribas,Jan Van Lunzen et al.
Joseph Gathe et al.
Background: Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF; Stribild(®)) is a recommended integrase inhibitor-based regimen in treatment guidelines from the US D...
Clinical Trial
The patient. 2015 Oct;8(5):445-54. DOI:10.1007/s40271-015-0137-9 2015
Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment [0.03%]
美国多发性硬化症患者对注射疗法的偏好：一种选择试验研究
Christine Poulos,Elizabeth Kinter,Jui-Chen Yang et al.
Christine Poulos et al.
Background and objective: Patients' perceptions and experiences of medication efficacy, medication adverse events, dosing frequency, and dosing complexity have been found to influence adherence to injectable disease-modif...
Evaluating a Decision Aid for Improving Decision Making in Patients with Early-stage Breast Cancer [0.03%]
评估乳腺癌早期患者改善决策的辅助工具的效果
Sarah T Hawley,Lisa Newman,Jennifer J Griggs et al.
Sarah T Hawley et al.
Background: Early-stage breast cancer patients face a series of complex treatment decisions, with the first typically being choice of locoregional treatment. There is a need for tools to support patients in this decision-...
What Matters to Women When Making Decisions About Breast Cancer Chemoprevention? [0.03%]
女性在决定是否进行乳腺癌化学预防时会考虑哪些因素？
Kathryn A Martinez,Angela Fagerlin,Holly O Witteman et al.
Kathryn A Martinez et al.
Purpose: Despite the effectiveness of chemoprevention (tamoxifen and raloxifene) in preventing breast cancer among women at high risk for the disease, uptake is low. The objective of this study was to determine the tradeo...
Patient-Centered Research to Support the Development of the Symptoms of Major Depressive Disorder Scale (SMDDS): Initial Qualitative Research [0.03%]
以患者为中心的研究支持抑郁症核心症状量表(SMDDS)的发展：初步定性研究
Kelly P McCarrier,Linda S Deal,Lucy Abraham et al.
Kelly P McCarrier et al.
Background: Content valid, patient-reported outcome (PRO) measures of major depressive disorder (MDD) symptoms are needed to assess MDD treatment benefit. While a range of questionnaires are currently available to evaluat...
Item Development and Face Validity of the Rheumatoid Arthritis Patient Priorities in Pharmacological Interventions Outcome Measures [0.03%]
类风湿关节炎患者药物干预优先结果测量的项目开发及表面效度研究
Tessa Sanderson,John Kirwan,Celia Almeida et al.
Tessa Sanderson et al.
Background: The assessment of rheumatoid arthritis (RA) is dominated by core sets and indices that have been developed by RA professionals. Previous research developed a set of eight priority treatment outcomes generated ...
Validity of a New Patient Engagement Measure: The Altarum Consumer Engagement (ACE) Measure [0.03%]
新型患者参与度衡量标准的有效性：Altarum消费者参与量表（ACE）
Christopher C Duke,Wendy D Lynch,Brad Smith et al.
Christopher C Duke et al.
Objective: The objective of this study was to report on the validation of new scales [called the Altarum Consumer Engagement (ACE) Measure] that are indicative of an individual's engagement in health and healthcare decisi...
Valuing Preferences for the Process and Outcomes of Clinical Genetics Services: A Pilot Study [0.03%]
临床遗传学服务过程和结果偏好的评估：一项试点研究
Ewan Gray,Martin Eden,Caroline Vass et al.
Ewan Gray et al.
Background: Understanding preferences for the process and outcomes of clinical genetics services (CGS) is a first step to developing these services appropriately. ...